Abstract 4CPS-123 Table 1
Chemotherapy regimensXPDCX
N (%) 171 (78%) 48 (22%)
Overall survival, months (CI 95%) p=0.2099 10.6 (9–12) 11.3 (9–16)
Progression-free survival, months (CI 95%) *p=0.0045 5.6* (5–6) 9.5* (7–12)